Download by
Scanning QR Code
No Stock Yet
Loading...
No Stock Yet
No Data
Bausch + Lomb Corporation reports Q1 results
Bausch + Lomb Corporation press release (NYSE:BLCO): Q1 Revenue of $889M (+0.9% Y/Y), increased organically by ~5% compared to the first quarter of 2021.Adjusted EBITDA was $170M for the first quarte
Bausch + Lomb Corporation Files Financial Statements for the First Quarter of 2022
PRNewswire 16-May-2022 7:17 PMVAUGHAN, ON, May 16, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helpi
Bausch + Lomb Announces Participation at the RBC Capital Markets Global Healthcare Conference
PRNewswire 13-May-2022 7:00 AMVAUGHAN, ON, May 13, 2022 /PRNewswire/ -- Bausch + Lomb Corporation, (TSX:BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see be
Bausch + Lomb release survey findings on macular edema treatment
Bausch + Lomb Corporation released findings from a survey designed to gain an understanding of retina specialists' need for a new treatment option for patients with macular edema associated with nonin
Bausch Health stock tries recovery but sees price target cut at BMO, BofA; Cowen starts Bausch+Lomb at Outperform
Bausch Health Companies (NYSE:BHC) stock rose ~7% on May 11, trying to pare of losses from a day ago when the stock closed -27.13% (May 10), following Q1 results. On Wednesday, the Canadian company sa
Cowen Initiates Bausch + Lomb at Outperform with $35 Price Target
12:41 PM EDT, 05/11/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
Upgrades According to Roth Capital, the prior rating for Hecla Mining Co (NYSE:HL) was changed from Neutral to Buy. In the first quarter, Hecla Mining showed an EPS of $0.01, compared to $0.06 from th
Bausch & Lomb analyst ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/11/2022 96.19% Cowen & Co. → $35 Initiates Coverage On → Outperform Data brought to you by Benzinga
Cowen & Co. Initiates Coverage On Bausch & Lomb with Outperform Rating, Announces Price Target of $35
Cowen & Co. analyst Ken Cacciatore initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Outperform rating and announces Price Target of $35.
Cowen starts Bausch + Lomb at Outperform with $35 price target
As previously reported, Cowen analyst Ken Cacciatore initiated coverage of Bausch + Lomb (BLCO) with an Outperform rating and $35 price target following the IPO conducted by parent Bausch Health (BHC)